Search for a trial

The effect of transcranial direct current stimulation on processing speed in patients after ischemic stroke

To evaluate the effects of tDCS on information processing speed in comparison to sham tDCS in patients after stroke with ascertained reduced processing speed. A proof of principle study.

A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 2a Safety, Tolerability, and Pharmacodynamic Study of Two Doses of an Histone Deacetylase Inhibitor (FRM-0334) in Subjects with Prodromal to Moderate Frontotemporal Dementia with Granulin Mutation

2.1 Primary Objectives• Evaluate the safety and tolerability of 2 fixed doses of FRM-0334 (300 and 500 mg daily in 2 sequential periods) over 28 days in subjects with prodromal to moderate FTD-GRN• Assess the PD effects of FRM-0334 on the change…

Intra-subject reliability of non-invasive brain stimulation on lower limb motor control

The objective is to assess the intra-subject reliability of tDCS induced effects on the reaction time in the lower extremities of healthy subjects.

Cognitive rehabilitation treatment of deficits in emotion, social cognition and regulation of behaviour after traumatic brain injury; evaluation of effect using a randomized controlled trial (RCT)

To investigate the treatment effect of the protocol Treatment of deficits in Emotion, Social Cognition and behaviour regulation (T-ScEMO) after traumatic brain injury.

A PHASE 1, SINGLE ASCENDING DOSE, MULTIPLE ASCENDING DOSE AND SINGLE DOSE FOOD EFFECT STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF LND101001 IN HEALTHY MALE AND FEMALE SUBJECTS

Primary objective: to assess the safety and tolerability and pharmacokinetics of LND101001 administered as single and multiple doses; Secondary: to assess the effect of food and gender on pharmacokinetics.

Effects of methylphenidate on the development of the dopaminergic system in the brain

Primary objective of the study: 1. To report on the effectmodification by age of MPH treatment on the outgrowth of the DA system using state-of-the-art Magnetic Resonance Imaging (MRI) techniquesSecondary objectives:1. To report on the…

Effectiveness of repetitive Transcranial Magnetic Stimulation (rTMS) treatment in patients with chronic tinnitus.

To study the effectiveness of low-frequency rTMS in patients with chronic tinnitus.

Auricular vagal nerve stimulation combined with rehabilitation to enhance functional outcome in cerebral palsy patients with upper extremity deficits (AVANS study) Part1

The ultimate goal is to investigate whether aVNS can enhance cortical plasticity and improve functional outcomes during intensive rehabilitation programs in children with cerebral palsy. First, we aim to establish the extent of cortical plasticity…

A Randomized, Double-blind, Placebo-controlled Single Ascending Dose and Open-label Multi-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ALN-APP in Adult Patients with Early-onset Alzheimer*s Disease (EOAD)

This study has been transitioned to CTIS with ID 2023-508363-79-00 check the CTIS register for the current data. Part AMain objectives: • To evaluate the safety and tolerability of single intrathecal (IT) doses of ALN-APP in adult patients with…

A Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ENX-102 at Plasma Steady State in Healthy Volunteers

To evaluate the safety and tolerability of ENX-102 following repeated doses in healthy volunteers

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel
Design, Prospective, 52-Week, Phase 2 Clinical Study to Evaluate the Safety and Efficacy of GV1001 Administered Subcutaneously for the Treatment of Mild to Moderate Alzheimer*s Disease

This study has been transitioned to CTIS with ID 2024-511610-20-00 check the CTIS register for the current data. Cognitive and functional abilities will be evaluated using psychometric scales (ie, cognitive subscale of the Alzheimer*s Disease…

A randomized, double-blind, placebo-controlled, parallel-group, phase 2 study to evaluate the safety and efficacy of CT1812 in subjects with mild to moderate Alzheimer's disease

The purpose of this study is to evaluate the safety and efficacy of two doses of the study drug CT1812 per day for six months in subjects with mild to moderate Alzheimer's disease. CT1812 will be compared with a placebo. A placebo is a product…

A Phase 1, Randomized, Double-Blind, Placebo- and Positive-Controlled, Parallel-Group Study to Evaluate the Effect of LMTM on the Response to an Oral Tyramine Challenge and to Determine the Multiple-Dose Pharmacokinetics of LMTM.

Part 1:The purpose of this study is to determine whether LMTM inhibits monoamine oxidase (MAO). MAO is an enzyme (protein involved in reactions in the body) which breaks down tyramine. By giving participants tyramine which raises the blood pressure…

A multicenter, randomized, double-blind, active-controlled study to evaluate the effects of LCZ696 compared to valsartan on cognitive function in patients with chronic heart failure and preserved ejection fraction

To evaluate the effects of LCZ696 compared to valsartan on cognitive function over 3 years in patients with HFpEF as assessed by the CogState cognitive assessment battery.

A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer*s Disease (AD)

The purpose of this study is to determine the effect of treatment on cognition, overall clinical status and underlying pathology in subjects with a risk of occurrence of the first clinical symptoms of Alzheimer's disease.People without…

A randomized, double-blind, placebo-controlled, two-cohort parallel group study to evaluate the efficacy of CAD106 and CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer*s disease

Primary objectives: * To demonstrate the effects of CAD106 and CNP520, respectively, vs. placebo on Time-to-event (TTE), with event defined as a diagnosis of MCI due to AD or dementia due to AD, whichever occurs first during the course of the study…